MYOS (MYOS) vs. Its Peers Head-To-Head Analysis

MYOS (NASDAQ: MYOS) is one of 531 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare MYOS to related companies based on the strength of its institutional ownership, analyst recommendations, earnings, dividends, risk, profitability and valuation.


This table compares MYOS and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MYOS -1,152.17% -117.13% -100.12%
MYOS Competitors -1,935.54% -92.21% -26.20%

Volatility & Risk

MYOS has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, MYOS’s rivals have a beta of 1.16, suggesting that their average share price is 16% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for MYOS and its rivals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MYOS 0 0 0 0 N/A
MYOS Competitors 3874 11264 25509 852 2.56

As a group, “Pharmaceutical preparations” companies have a potential upside of 65.27%. Given MYOS’s rivals higher possible upside, analysts clearly believe MYOS has less favorable growth aspects than its rivals.

Institutional & Insider Ownership

1.7% of MYOS shares are held by institutional investors. Comparatively, 46.8% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 47.3% of MYOS shares are held by insiders. Comparatively, 15.0% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares MYOS and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
MYOS $530,000.00 -$4.05 million -1.62
MYOS Competitors $2.18 billion $164.12 million -1.74

MYOS’s rivals have higher revenue and earnings than MYOS. MYOS is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.


MYOS rivals beat MYOS on 7 of the 10 factors compared.

MYOS Company Profile

MYOS RENS Technology Inc., a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity. Its products include Re Muscle Health products, a direct-to-consumer portfolio of muscle health bars, meal replacement shakes, and daily supplement powders; and Qurr line of products comprising flavored puddings, powders, and shakes. The company sells its Re Muscle Health products through e-commerce Website; and Qurr line of products through convenient direct online ordering without a prescription. MYOS RENS Technology Inc. has a research agreement with the University of California to study the effects Of Fortetropin on skeletal muscle protein synthetic rate in older men and women; and Rutgers University for the discovery development and commercialization of products that improve muscle health and performance. The company was formerly known as MYOS Corporation and changed its name to MYOS RENS Technology Inc. in March 2016. MYOS RENS Technology Inc. was founded in 2007 and is based in Cedar Knolls, New Jersey.

Receive News & Ratings for MYOS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS and related companies with's FREE daily email newsletter.

Leave a Reply